Search Results - oncology

79 Results

Sort By:

Inhibitors of the N-terminal Domain of the Androgen Receptor (UCLA Case No. 2023-075)

Researchers at UCLA under the guidance of Drs. Matthew Rettig and Michael Jung have developed novel molecular compounds that reduce growth of prostate cancer cells. Dr. Jung in collaboration with Dr. Rettig have furthered the development of these compounds by synthesizing a new series of analogues that have similar inhibitory effects. BACKGROUND: Prostate...

Published: 9/23/2024 | Inventor(s): Matthew Rettig, Michael Jung

Keywords(s): androgen receptor therapy, castration resistant prostate cancer, Oncology, Oncology (Small Molecules, Peptides and Antibodies), prostate cancer, small molecules

Category(s): Therapeutics > Oncology, Therapeutics > Oncology > Oncology (Small Molecules)

Methods and Compositions for Treating Melanoma (UCLA Case No. 2021-324)

The Graeber Laboratory at UCLA discovered a novel mechanism for treating melanoma using ferroptosis, a type of programmed cell death, that shows promise against therapy resistance. BACKGROUND: Melanoma is a highly aggressive skin cancer that spreads throughout the body and can be fatal if left untreated. Therapies for melanoma range from immunotherapy...

Published: 7/10/2024 | Inventor(s): Thomas Graeber

Keywords(s): Cancer, ferroptosis, Immunotherapy, MAPK signaling, Melanoma, Oncology, Skin, tumor resistance

Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy

Temporal Transcriptomic Characterization of Small Cell Neuroendocrine Prostate Cancer (UCLA Case No. 2023-268)

The laboratory of Dr. Thomas Graeber at UCLA developed a novel in vivo model that can characterize mechanisms of the trans-differentiation of prostate cancer into small cell neuroendocrine cancer. BACKGROUND: Prostate cancer is one of the most common cancers among men worldwide, with an estimated 288,300 new cases in the U.S. last year. Among many...

Published: 10/4/2024 | Inventor(s): Thomas Graeber

Keywords(s): neuroendocrine, Oncology, prostate cancer, small cell cancer, transdifferentiation

Category(s): Therapeutics > Oncology > Oncology (Small Molecules), Platforms > Diagnostic Platform Technologies

Multi-Phasic Therapeutic Delivery System (UCLA Case No. 2020-396)

Researchers in the Department of Radiological Sciences at UCLA have conceived a new methodology to overcome obstacles arising after the treatment of tumors by accessing their vascular supply by 1) targeting tumor vessels 2) delivering antineoplastic agents (e.g., chemotherapy or immunotherapy) and 3) delivering anti-angiogenic therapy to reduce blood...

Published: 7/10/2024 | Inventor(s): Antoinette Gomes

Keywords(s): Anti-Angiogenics, Multiphasic and Multitemporal, Oncology, Therapeutics, Vascular therapy

Category(s): Therapeutics > Oncology, Medical Devices

Antitumor activity of NKTR-214 alone or in combination with anti-PD-1 therapy in tumors resistant to anti-PD-1 (UCLA Case No. 2019-254)

UCLA researchers have discovered a therapy for anti-PD-1 resistant tumors in colon carcinoma patients. A small molecule therapeutic alone or in combination with immune-checkpoint blockade (ICB) therapy exhibits tumor remission even in sublines with mutated signalling pathways that have rendered them ICB resistant. BACKGROUND: Immunotherapy, the...

Published: 2/15/2024 | Inventor(s): Antoni Ribas

Keywords(s): Colon carcinoma, Immune checkpoint blockade, Immunotherapy, Oncology, Oncology (Small Molecules, Peptides and Antibodies), PD-1, PD-L1, Resistant tumors, Signaling pathways, Small molecule therapeutics, Tumor

Category(s): Life Science Research Tools, Therapeutics > Oncology > Oncology Immunotherapy, Therapeutics > Oncology > Oncology (Small Molecules)

2022-291: Methods for Identifying and Correcting Tumor Humoral Immune Dysfunction

UCLA researchers in the Department of Bioengineering have developed a platform advancing systems serology that profiles the Fc properties of anti-tumor antibodies (ATAbs) to provide more nuanced understanding of a cancer’s humoral immunity and better guide therapeutic approaches towards overcoming the immune dysregulation. BACKGROUND: Antibodies...

Published: 2/15/2024 | Inventor(s): Aaron Meyer

Keywords(s): antibody Fc profiling, Anti-tumor antibodies, anti-tumor immune response, ATAbs, Cancer, immune evasion, Oncology, systems serology

Category(s): Diagnostic Markers > Cancer, Platforms > Diagnostic Platform Technologies

2020-363 ROTATIONAL INTENSITY MODULATION FOR ULTRA HIGH DOSE RATE (FLASH) X-RAY DOSE DELIVERY

Summary: UCLA researchers in the Department of Radiation Oncology have developed a collimation device that can achieve ultrafast delivery and complex dose modulation for x-ray radiotherapy. Background: Radiotherapy aims to treat and control the growth of tumors via exposure to high doses of ionizing radiation. While it is generally effective, it...

Published: 7/19/2023 | Inventor(s): Ke Sheng, Qihui Lyu

Keywords(s): Hospital Systems And Devices, Medical Device, Oncology, Radiation Therapy, X-Ray

Category(s): Therapeutics > Radiology, Therapeutics > Oncology, Therapeutics > Radiology > Radiomitigation

2020-179 A METHOD TO PREPARE DEAD TUMOR CELLS AND USE THEREOF

SUMMARYUCLA researchers in the Department of Bioengineering have developed a novel method to generate dead tumors cells for use in cancer therapeutics.BACKGROUNDCancer is a deadly disease that causes approximately 10 million yearly deaths across the globe. While solid tumors may often be fully resected by surgery, the treatment of hematologic malignancies...

Published: 9/5/2023 | Inventor(s): Zhen Gu

Keywords(s): Medical Devices and Materials, Oncology, Therapeutics & Vaccines

Category(s): Therapeutics > Oncology

2019-863 METHODS CONCERNING ONGOING TREATMENT FOR CANCER

UCLA researchers in the Department of Molecular, Cell, and Developmental Biology have developed a novel biomarker detection method for circulating blood cell-free RNA. BACKGROUND: Approximately 39% of men and women will be diagnosed with cancer at some point during their lifetimes. Circulating tumor cell-free DNA (cfDNA) is being increasingly used...

Published: 7/19/2023 | Inventor(s): Matteo Pellegrini, Eri Srivatsan

Keywords(s): Diagnostic Markers & Platforms, Life Science Research Tools, Nucleic Acid Platform Systems, Nucleic Acids, Oncology

Category(s): Life Science Research Tools > Plasmids/Vectors, Life Science Research Tools, Diagnostic Markers, Platforms > Drug Delivery > Nucleic Acids

2020-784 DEVELOPMENT OF A STING DELIVERING NANOPARTICLE FOR IMMUNOTHERAPY OF CANCER METASTASES TO THE LIVER

UCLA researchers in the Department of Nanomedicine have developed antigen presenting cells (APCs) targeting nanoparticles to deliver STING (stimulator of interferon genes) agonists to the liver for metastatic cancer treatment. BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy and estimated to become the second leading...

Published: 7/19/2023 | Inventor(s): Andre Nel

Keywords(s): Drug Delivery, Immunotherapy, Nanoparticles, Oncology, Therapeutics & Vaccines

Category(s): Platforms > Drug Delivery, Therapeutics, Platforms > Drug Delivery > Nanoparticles, Therapeutics > Immunology And Immunotherapy, Therapeutics > Oncology, Therapeutics > Oncology > Oncology Immunotherapy, Materials > Nanotechnology

1 2 3 4 5 6 7 8